Please use the contact form to send an email and check back soon.
What's new
- Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Date of authorisation: 25/06/2025, Revision: 5, Status: Authorised
- Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 8, Status: Authorised
- Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Date of authorisation: 06/02/2009, Revision: 27, Status: Authorised
- Human medicines European public assessment report (EPAR): Zarzio, filgrastim, Date of authorisation: 06/02/2009, Revision: 29, Status: Authorised
- Human medicines European public assessment report (EPAR): Amyvid, florbetapir (18F), Date of authorisation: 14/01/2013, Revision: 17, Status: Authorised
- Human medicines European public assessment report (EPAR): Vydura, rimegepant, Date of authorisation: 25/04/2022, Revision: 9, Status: Authorised
- Human medicines European public assessment report (EPAR): Instanyl, fentanyl, Date of authorisation: 20/07/2009, Revision: 42, Status: Authorised